LEO Pharma

LEO Pharma is a global pharmaceutical company specialising in medical dermatology, with a strong focus on inflammatory and immune‑mediated skin conditions that often overlap with allergic disease, including atopic dermatitis (eczema) and chronic hand eczema. The company is dedicated to improving outcomes for people living with conditions where allergy plays a significant role in disease burden and quality of life.

Within the allergy space, LEO Pharma supports the development of evidence‑based treatments, real‑world research, and patient‑centred education initiatives aimed at improving clinical understanding, earlier diagnosis, and holistic care. This includes collaboration with patient organisations and healthcare professionals to explore the physical, psychological, and social impact of allergic and inflammatory skin conditions, such as its work on the Chronic Hand Eczema (CHE) Patient Impact Report in partnership with Allergy UK.

LEO Pharma also invests significantly in research and innovation, advancing new therapies for allergic and inflammatory dermatological conditions, particularly atopic dermatitis, through topical, biologic, and systemic treatments. Its work is underpinned by a commitment to non‑promotional, educational activity that supports patients, carers, and healthcare professionals alike.